tiprankstipranks
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY

Alnylam Pharma (ALNY) Income Statement

1,044 Followers

Alnylam Pharma Income Statement

Last quarter (Q4 2023), Alnylam Pharma's total revenue was $439.72M, a decrease of -26.64% from the same quarter last year. In Q4, Alnylam Pharma's net income was $-137.87M. See Alnylam Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 1.82B$ 1.83B$ 1.04B$ 1.20M$ 492.85M$ 219.75M
Cost of Revenue
$ 308.97M$ 310.41M$ 140.17M$ -115.00M$ 78.05M$ 25.06M
Gross Profit
$ 1.53B$ 1.52B$ 897.24M$ 1.37B$ 414.80M$ 194.69M
Operating Expense
$ 1.80B$ 1.80B$ 1.65B$ 1.41B$ 1.24B$ 1.13B
Operating Income
$ -262.11M$ -282.18M$ -785.07M$ -45.32M$ -828.44M$ -939.43M
Net Non Operating Interest Income Expense
$ -25.66M$ -25.66M$ -155.97M$ -143.02M$ -72.69M$ 33.45M
Other Income Expense
$ 125.68M$ -125.68M$ 185.95M$ 471.00K$ 45.52M$ 20.73M
Pretax Income
$ -433.52M$ -433.52M$ -1.13B$ -852.14M$ -855.60M$ -885.25M
Tax Provision
$ 6.72M$ 6.72M$ 4.16M$ 680.00K$ 2.68M$ 863.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -430.57M$ -440.24M$ -171.36M$ -189.49M$ -858.28M$ -886.12M
Basic EPS
$ -3.53$ -3.52$ -9.30$ -7.20$ -7.46$ -8.11
Diluted EPS
$ -3.61$ -3.52$ -9.30$ -7.20$ -7.46$ -8.11
Basic Average Shares
$ 499.62M$ 124.91M$ 121.69M$ 118.45M$ 114.99M$ 109.26M
Diluted Average Shares
$ 499.62M$ 124.91M$ 121.69M$ 118.45M$ 114.99M$ 109.26M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
----$ -6.38$ -6.70
Reported Normalized Diluted E P S
----$ -6.38$ -6.70
Rent Expense Supplemental
------
Total Expenses
$ 2.34B$ 2.11B$ 1.79B$ 1.30B$ 1.32B$ 1.16B
Net Income From Continuing And Discontinued Operation
$ -440.24M$ -440.24M$ -1.13B$ -189.49M$ -858.28M$ -886.12M
Normalized Income
$ -206.31M$ -342.48M$ -890.32M-$ -885.19M$ -894.36M
Interest Expense
----$ 84.50M$ 0.00
EBIT
$ -312.30M$ -312.30M$ -971.02M$ -709.12M$ -771.10M$ -885.25M
EBITDA
$ -255.84M$ -215.26M$ -929.94M$ -667.00M$ -736.33M$ -868.08M
Currency in USD

Alnylam Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis